Article
Paying down more debt, Takeda offloads prescription drug portfolio for $562 million
Rating:
0.0
Views:
85
Likes:
1
Library:
1
It's been two years since Takeda's $62 billion Shire buyout, and the Tokyo biotech is still restructuring. The company struck a deal with Germany-based Cheplapharm to divest some non-core prescription products for an upfront payment of $562 million. The portfolio — which includes cardiovascular, metabolic and anti-inflammatory drugs sold mostly
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value